Skip to content

Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy.

Qibin Chen, Jun Dong, Jie Luo, Li Ren, S. Min, Xuechao Hao, Q. Luo, Jianmei Chen, Xiao Li

Journal of ECT January 6, 2020 DOI: 10.1097/yct.0000000000000636 via Semantic Scholar

Summary

Adding a low dose of ketamine to electroconvulsive therapy (ECT) for major depressive disorder does not improve overall response, remission, or relapse rates, but it does speed up the treatment's effects. Patients receiving 0.3 mg/kg ketamine before ECT required fewer sessions to achieve a response (median 4 vs. 7 sessions) and remission (median 8 vs. 9 sessions), and also reduced suicidal ideation more quickly (median 3 vs. 6 sessions). The findings suggest ketamine can accelerate the onset of ECT's antidepressant benefits without affecting long-term relapse.

Study at a glance

Characteristics Randomized controlled trial Placebo-controlled Double-blind Peer reviewed
Sample size 127
Population Patients with major depressive disorder
Keywords Medicine
Citations 22
Key finding Low-dose ketamine accelerates the onset of antidepressant effects and reduces the number of ECT sessions needed for response, remission, and reduction of suicidal ideation, but does not affect overall relapse rates.

Abstract

OBJECTIVES It remains controversial whether a subanesthetic dose of ketamine could modulate the antidepressant effect of electroconvulsive therapy (ECT) in patients with major depressive disorder. We investigated the effect of ketamine on accelerating the antidepressant efficacy of ECT. METHODS One hundred twenty-seven patients with major depressive disorder were included in this randomized, placebo-controlled, double-blind study. The study group received 0.3 mg/kg ketamine, and the control group received an isovolumetric dose of normal saline before undergoing ECT under propofol anesthesia. The main outcome was the Hamilton Depression Rating Scale score after each ECT session. Suicidal ideation (SI) was also evaluated using the Hamilton Depression Rating Scale. The response, remission, and recurrence rates were analyzed using time-to-event analysis. RESULTS No significant differences were found in the overall response, remission, and relapse rates between the groups (P > 0.05). The median number of ECT sessions for achieving response was 4.0 ± 0.41 in the study group and 7.0 ± 0.79 in the control group (P < 0.05). The median number of ECT sessions for achieving remission in the study and control groups was 8.0 ± 0.29 and 9.0 ± 0.48, respectively (P < 0.05). The median number of ECT sessions for achieving SI reduction in the study and control groups was 3.0 ± 0.75 and 6.0 ± 1.19, respectively (P < 0.05). CONCLUSIONS Low-dose ketamine (0.3 mg/kg) could modulate the antidepressant efficacy of ECT via accelerating the onset of its effects and reducing the number of ECT sessions required to obtain response, remission, and SI reduction, without influencing the relapse rates in remitting patients after ECT treatment.

Comments

No comments yet.

Log in to comment